Cefuroxime and Eosinophilia - a phase IV clinical study of FDA data

Summary:

Eosinophilia is reported as a side effect among people who take Cefuroxime (cefuroxime sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Macular oedema.

The phase IV clinical study analyzes which people have Eosinophilia when taking Cefuroxime. It is created by eHealthMe based on reports of 12,808 people who have side effects when taking Cefuroxime from the FDA, and is updated regularly.

What is Cefuroxime?

Cefuroxime has active ingredients of cefuroxime sodium. It is often used in sinusitis. eHealthMe is studying from 12,999 Cefuroxime users. Check the latest studies of Cefuroxime.

What is Eosinophilia?

Eosinophilia (eosinophil count in the peripheral blood exceeds) is found to be associated with 956 drugs and 1,398 conditions by eHealthMe. Check the latest studies of Eosinophilia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

12,808 people reported to have side effects when taking Cefuroxime.
Among them, 63 people (0.49%) have Eosinophilia.

Among these 63 people:

How long have people been on Cefuroxime when they have Eosinophilia? *

What is the gender of people who have Eosinophilia when taking Cefuroxime? *

female: 51.72 %
male: 48.28 %

What is the age of people who have Eosinophilia when taking Cefuroxime? *

What are other drugs people take besides Cefuroxime? *

What are other side effects people have besides Eosinophilia? *

Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 25 people, 39.68%
Rashes (redness): 20 people, 31.75%
Fever: 19 people, 30.16%
Leukocytosis (increased white blood cells): 13 people, 20.63%
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 9 people, 14.29%
Rash Erythematous (redness of the skin): 9 people, 14.29%
Erythema Multiforme (a type of hypersensitivity reaction): 8 people, 12.70%
Dyspnea (difficult or laboured breathing): 7 people, 11.11%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 7 people, 11.11%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 9.52%

What are the existing conditions these people have? *

Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 11 people, 17.46%
Device Related Infection: 7 people, 11.11%
Pain: 6 people, 9.52%
Fever: 5 people, 7.94%
Respiratory Tract Infection: 3 people, 4.76%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 4.76%
High Blood Pressure: 3 people, 4.76%
Diabetes: 2 people, 3.17%
Stress And Anxiety: 2 people, 3.17%
Upper Respiratory Tract Infection: 1 person, 1.59%

* Approximation only. Some reports may have incomplete information.

Do you take Cefuroxime and have Eosinophilia?

- Check whether Eosinophilia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cefuroxime:

Cefuroxime (12,999 reports)

Eosinophilia treatments and more:

Eosinophilia (20,276 reports)

Browse all side effects of Cefuroxime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eosinophilia:

Eosinophilia (956 drugs)

Browse all the conditions that are associated with Eosinophilia:

Eosinophilia (1,398 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cefuroxime sodium (the active ingredients of Cefuroxime) and Cefuroxime (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.